Loading
Life sciences · Journal article
World Journal of Surgical Oncology · September 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Since the introduction of therapies based on anti-human epidermal growth factor receptor 2 (HER2), researchers have increasingly focused on HER2-low breast cancer (BC). Here, we compared clinicopathological traits, response to treatment, and prognosis of BC categorized as HER2-low and HER2-zero under neoadjuvant chemotherapy (NAC) setting. We retrospectively examined data collected from 554 HER2-negative BC patients who were prospectively enrolled at two institutions between January 2015 and June 2023. HER2-negative BC was categorized into two types: HER2-low and HER2-zero. We compared clinicopathological traits, pathological complete response (pCR), and long-term survival of HER2-low and HER2-zero BC patients. ypT0/isN0 is defined as pathological complete response (pCR), meaning no invasive carcinoma is shown in axillary lymph nodes or breast, regardless of the presence of ductal carcinoma in situ. The median follow-up was 62 months, with 11 patients lost to follow-up. The HER2-low and HER2-zero BC groups comprised 313 and 241 patients, respectively. Hormone receptor (HR) status-based stratification revealed that 269 and 285 patients showed HR-positive (HR+) and HR-negative (HR–) BC, respectively. In subgroup analysis, statistic differences in clinical N stage and tumor grade were noted in HER2-low and HER2-zero BC patients in the HR+ cohort ( P = 0.011 and 0.036, respectively). Among HR– patients, clinical T stage of HER2-low and HER2-zero BC patients differed ( P = 0.022). In multivariate analysis, pCR did not correlate with HER2 status in HR + and HR– cohorts ( P = 0.608 and 0.938, respectively). Moreover, in HR + and HR– cohorts, HER2-low BC patients and HER2-zero BC patients had almost comparable 5-year overall survival (OS) and disease-free survival (DFS) rates (both P > 0.05). Patient survival (OS and DFS) and HER2 status showed no interaction in multivariate analysis (both P > 0.05). HER2-low BC exhibited distinct clinicopathological features compared to HER2-zero BC; this difference was also noted across HR status. However, these differences do not translate into effects on treatment response to NAC and patient prognosis.